Novel long‐acting ropeginterferon alfa‐2b: Pharmacokinetics, pharmacodynamics and safety in a phase I clinical trial

202130 citationsJournal Articlebronze Open Access

Authors

Yi‐Wen Huang · National Taiwan University

Albert Qin

Jane Fang · Athenex (United States)

Richard Larouche · Syneos Health (United States)

Abstract

Ropeginterferon alfa-2b up to 270 μg was safe and well tolerated. The PK/PD parameters of ropeginterferon alfa-2b showed increase in dose-response. Ropeginterferon alfa-2b had higher drug exposures and showed similar safety profile when compared to pegylated IFN alfa-2a at the same dose level.

Topics & Keywords

Hepatitis C virus research Systemic Lupus Erythematosus Research Cytokine Signaling Pathways and Interactions

Publication Details

Published in: British Journal of Clinical Pharmacology

Volume 88, Issue 5, pp. 2396-2407

DOI: 10.1111/bcp.15176

Field-Weighted Citation Impact: 2.25

Command Palette

Novel long‐acting ropeginterferon alfa‐2b: Pharmacokinetics, pharmacodynamics and safety in a phase I clinical trial

Authors

Abstract

Topics & Keywords

Publication Details